ADAMTS13

ADAMTS13protein

ADAMTS13 deficiency permits ultralarge VWF multimer accumulation, amplifying platelet adhesion and thrombotic risk in acute coronary events.

Pathway placement

Cascade stepEndothelial activation & erosion

Confidencehigh

RationaleVWF multimer-size regulator; endothelial dysfunction marker; imbalance drives platelet hyperadhesion.

Also acts inPlatelet activation

Druggability

DruggableYes

Known drugs / candidates1

Small-molecule tractableYes

Antibody tractableYes

EnsemblENSG00000160323

Type I vs Type II discrimination

ScoresIndeterminate

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)+25

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationn/a

2anemia / acute blood lossmag 3

3hypovolemia / dehydrationn/a

4tachyarrhythmiamag 0

5hypoxemia / respiratory failuren/a

6hypertensive emergencymag 0

7high-demand / peri-operative stressmag 2

Coverage: 4/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 5 supporting references. See the discrimination table for all markers.

Validated clinical assay

Specimen

Platelet-poor plasma

Collection tube

Sodium citrate 3.2% (light blue-top)

Method / principle

FRET-based activity assay

Reagent / substrate

FRETS-VWF73 fluorogenic substrate

Platform

Fluorometer / ELISA

Turnaround · availability

Send-out · Reference lab